Cargando…
Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR
Metabolic syndrome is a complex of interrelated risk factors for cardiovascular disease and diabetes. Thus, new point-of-care diagnostic tools are essential for unambiguously distinguishing MetS patients, providing results in rapid time. Herein, we evaluated the potential of Fourier transform infrar...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855898/ https://www.ncbi.nlm.nih.gov/pubmed/36671850 http://dx.doi.org/10.3390/bios13010015 |
_version_ | 1784873488635396096 |
---|---|
author | Tkachenko, Kateryna Esteban-Díez, Isabel González-Sáiz, José M. Pérez-Matute, Patricia Pizarro, Consuelo |
author_facet | Tkachenko, Kateryna Esteban-Díez, Isabel González-Sáiz, José M. Pérez-Matute, Patricia Pizarro, Consuelo |
author_sort | Tkachenko, Kateryna |
collection | PubMed |
description | Metabolic syndrome is a complex of interrelated risk factors for cardiovascular disease and diabetes. Thus, new point-of-care diagnostic tools are essential for unambiguously distinguishing MetS patients, providing results in rapid time. Herein, we evaluated the potential of Fourier transform infrared spectroscopy combined with chemometric tools to detect spectra markers indicative of metabolic syndrome. Around 105 plasma samples were collected and divided into two groups according to the presence of at least three of the five clinical parameters used for MetS diagnosis. A dual classification approach was studied based on selecting the most important spectral variable and classification methods, linear discriminant analysis (LDA) and SIMCA class modelling, respectively. The same classification methods were applied to measured clinical parameters at our disposal. Thus, the classification’s performance on reduced spectra fingerprints and measured clinical parameters were compared. Both approaches achieved excellent discrimination results among groups, providing almost 100% accuracy. Nevertheless, SIMCA class modelling showed higher classification performance between MetS and no MetS for IR-reduced variables compared to clinical variables. We finally discuss the potential of this method to be used as a supportive diagnostic or screening tool in clinical routines. |
format | Online Article Text |
id | pubmed-9855898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98558982023-01-21 Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR Tkachenko, Kateryna Esteban-Díez, Isabel González-Sáiz, José M. Pérez-Matute, Patricia Pizarro, Consuelo Biosensors (Basel) Article Metabolic syndrome is a complex of interrelated risk factors for cardiovascular disease and diabetes. Thus, new point-of-care diagnostic tools are essential for unambiguously distinguishing MetS patients, providing results in rapid time. Herein, we evaluated the potential of Fourier transform infrared spectroscopy combined with chemometric tools to detect spectra markers indicative of metabolic syndrome. Around 105 plasma samples were collected and divided into two groups according to the presence of at least three of the five clinical parameters used for MetS diagnosis. A dual classification approach was studied based on selecting the most important spectral variable and classification methods, linear discriminant analysis (LDA) and SIMCA class modelling, respectively. The same classification methods were applied to measured clinical parameters at our disposal. Thus, the classification’s performance on reduced spectra fingerprints and measured clinical parameters were compared. Both approaches achieved excellent discrimination results among groups, providing almost 100% accuracy. Nevertheless, SIMCA class modelling showed higher classification performance between MetS and no MetS for IR-reduced variables compared to clinical variables. We finally discuss the potential of this method to be used as a supportive diagnostic or screening tool in clinical routines. MDPI 2022-12-23 /pmc/articles/PMC9855898/ /pubmed/36671850 http://dx.doi.org/10.3390/bios13010015 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tkachenko, Kateryna Esteban-Díez, Isabel González-Sáiz, José M. Pérez-Matute, Patricia Pizarro, Consuelo Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR |
title | Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR |
title_full | Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR |
title_fullStr | Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR |
title_full_unstemmed | Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR |
title_short | Dual Classification Approach for the Rapid Discrimination of Metabolic Syndrome by FTIR |
title_sort | dual classification approach for the rapid discrimination of metabolic syndrome by ftir |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855898/ https://www.ncbi.nlm.nih.gov/pubmed/36671850 http://dx.doi.org/10.3390/bios13010015 |
work_keys_str_mv | AT tkachenkokateryna dualclassificationapproachfortherapiddiscriminationofmetabolicsyndromebyftir AT estebandiezisabel dualclassificationapproachfortherapiddiscriminationofmetabolicsyndromebyftir AT gonzalezsaizjosem dualclassificationapproachfortherapiddiscriminationofmetabolicsyndromebyftir AT perezmatutepatricia dualclassificationapproachfortherapiddiscriminationofmetabolicsyndromebyftir AT pizarroconsuelo dualclassificationapproachfortherapiddiscriminationofmetabolicsyndromebyftir |